公开(公告)号：US20230301978A1

公开(公告)日：2023-09-28

申请号：US17975765

申请日：2022-10-28

Applicant: Exelixis, Inc.

Inventor： Khalid Shah ,  Gisela Schwab ,  Steven Lacy

IPC: A61K31/47 ,  A61P35/00 ,  A61K9/00

CPC classification number: A61K31/47 ,  A61P35/00 ,  A61K9/0053

Abstract: This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma in patients in need thereof.

公开(公告)号：US20220087999A1

公开(公告)日：2022-03-24

申请号：US17538310

申请日：2021-11-30

Applicant: Exelixis, Inc.

Inventor： Jo Ann Wilson ,  Khalid Shah

IPC: A61K31/47 ,  A61K9/20 ,  A61K45/06 ,  A61K9/28

Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.

公开(公告)号：US20220031688A1

公开(公告)日：2022-02-03

申请号：US17505307

申请日：2021-10-19

Applicant: Exelixis, Inc.

Inventor： Jo Ann Wilson ,  Khalid Shah

IPC: A61K31/47 ,  A61K9/28 ,  A61K9/20 ,  A61K45/06

Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.

公开(公告)号：US11123338B2

公开(公告)日：2021-09-21

申请号：US16722563

申请日：2019-12-20

Applicant: Exelixis, Inc.

Inventor： Jo Ann Wilson ,  Khalid Shah

IPC: A61K31/47 ,  A61K9/20 ,  A61K9/28 ,  A61K45/06

Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.

公开(公告)号：US20210161885A1

公开(公告)日：2021-06-03

申请号：US17170275

申请日：2021-02-08

Applicant: Exelixis, Inc.

Inventor： Jo Ann Wilson ,  Khalid Shah

IPC: A61K31/47 ,  C07D215/233

Abstract: The present invention is directed to processes for making and compositions containing quinolines such as formula I or pharmaceutically acceptable salts thereof wherein: X1 is H, Br, CI, or X2 is H, Br, CI, or n1 is 1-2; and n2 is 1-2.

公开(公告)号：US20200268737A1

公开(公告)日：2020-08-27

申请号：US16620379

申请日：2018-06-08

Applicant: Exelixis, Inc.

Inventor： Khalid Shah ,  Gisela Schwab ,  Steven Lacy

IPC: A61K31/47 ,  A61K9/00 ,  A61P35/00

Abstract: This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma in patients in need thereof.

公开(公告)号：US20250134880A1

公开(公告)日：2025-05-01

申请号：US19007899

申请日：2025-01-02

Applicant: Exelixis, Inc.

Inventor： Jo Ann Wilson ,  Khalid Shah

IPC: A61K31/47 ,  A61K9/20 ,  A61K9/28 ,  A61K45/06

Abstract: Pharmaceutical compositions and unit dosage forms comprising Compound (I) are disclosed.

公开(公告)号：US12017995B2

公开(公告)日：2024-06-25

申请号：US17312658

申请日：2019-12-12

Applicant: Exelixis, Inc.

Inventor： Frenel DeMorin ,  Khalid Shah ,  Sagar Shakya ,  Peter Wong ,  Courtney S. Johnson ,  Melanie Janelle Bevill ,  Stephan D. Parent

IPC: C07D215/48 ,  A61K31/47

CPC classification number: C07D215/48 ,  C07B2200/13

Abstract: The present invention relates to crystalline forms of the free base of the c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of salts of Compound 1. The invention also relates to pharmaceutical compositions comprising the solid polymorphs of the free base and salts of Compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase.

公开(公告)号：US12016854B2

公开(公告)日：2024-06-25

申请号：US17975765

申请日：2022-10-28

Applicant: Exelixis, Inc.

Inventor： Khalid Shah ,  Gisela Schwab ,  Steven Lacy

IPC: A61K31/47 ,  A61K9/00 ,  A61P35/00

CPC classification number: A61K31/47 ,  A61K9/0053 ,  A61P35/00

Abstract: This invention relates to a liquid pharmaceutical composition comprising cabozantinib to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma in patients in need thereof.

公开(公告)号：US20240010621A1

公开(公告)日：2024-01-11

申请号：US18344267

申请日：2023-06-29

Applicant: Exelixis, Inc.

Inventor： Khalid Shah

IPC: C07D215/22

CPC classification number: C07D215/22 ,  C07B2200/13

Abstract: The invention relates to novel crystalline solid forms of salts of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly renal cell carcinoma (RCC) and medullary thyroid cancer (MTC).